Cargando…

Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

BACKGROUND: Pancreatic cancer remains one of the deadliest cancers due to lack of early detection and absence of effective treatments. Gemcitabine, the current standard-of-care chemotherapy for pancreatic cancer, has limited clinical benefit. Treatment of pancreatic cancer cells with gemcitabine has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yip-Schneider, Michele T, Wu, Huangbing, Stantz, Keith, Agaram, Narasimhan, Crooks, Peter A, Schmidt, C Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672012/ https://www.ncbi.nlm.nih.gov/pubmed/23590467 http://dx.doi.org/10.1186/1471-2407-13-194

Ejemplares similares

Dimethylaminoparthenolide (DMAPT) as an alternative approach for treatment of Familial Mediterranean Fever (FMF)
por: Mosayebian, Ali, et al.
Publicado: (2021)

Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease
por: Klein, Julie, et al.
Publicado: (2020)

Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer()()
por: Knoop, Richard F., et al.
Publicado: (2014)

NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair
por: Deraska, Peter V., et al.
Publicado: (2018)

Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma
por: Ellsworth, Katarzyna A., et al.
Publicado: (2013)

SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
por: Ramu, Iswarya, et al.
Publicado: (2019)

Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
por: Saiki, Yuriko, et al.
Publicado: (2021)

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer
por: Li, Liang, et al.
Publicado: (2016)

Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
por: Inkoom, Andriana, et al.
Publicado: (2020)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

Development of a mathematical model to estimate intra-tumor oxygen concentrations through multi-parametric imaging
por: Lee, Chung-Wein, et al.
Publicado: (2016)

Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models
por: Capello, Michela, et al.
Publicado: (2013)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2016)

Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance
por: Zhang, Ya-Jing, et al.
Publicado: (2017)

The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma
por: Vitellius, Carole, et al.
Publicado: (2018)

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy
por: Chao, Ying-Jui, et al.
Publicado: (2014)

Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
por: Wendling, Thierry, et al.
Publicado: (2016)

The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance
por: Elaskalani, Omar, et al.
Publicado: (2017)

Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
por: Kim, Myoungjae, et al.
Publicado: (2019)

Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

Pancreas Cancer Survival in the Gemcitabine Era
por: Wachtel, Mitchell S., et al.
Publicado: (2008)

Multifocal High-Grade Pancreatic Precursor Lesions: A Case Series and Management Recommendations
por: Soufi, Mazhar, et al.
Publicado: (2019)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Barriers and opportunities for gemcitabine in pancreatic cancer therapy
por: Beutel, Alica K., et al.
Publicado: (2023)

Determinants of gemcitabine response in pancreatic cancer: are we there?
por: Fitzpatrick, Orla M., et al.
Publicado: (2023)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer
por: Tran Cao, Hop S., et al.
Publicado: (2010)

Cytopathologic features of epithelioid hemangioendothelioma including touch imprints for rapid on-site evaluation
por: Lahori, Mega, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1sa9r25tmld0f9afluq29c11lr